Putting trials on trial - the costs and consequences of small trials in depression: A systematic review of methodology

Journal of Epidemiology and Community Health

Volumn 51, Issue 4, 1997, Pages 354-358

  Hotopf, Matthew ^a   Lewis, Glyn ^b   Normand, Charles ^b  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; SEROTONIN UPTAKE INHIBITOR; TRICYCLIC ANTIDEPRESSANT AGENT;

ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; ECONOMIC EVALUATION; FOLLOW UP; HEALTH CARE COST; HUMAN; MANAGEMENT; MEASUREMENT; MEDICAL RESEARCH; META ANALYSIS; METHODOLOGY; QUALITY OF LIFE; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; STATISTICAL ANALYSIS;

EID: 0030768193     PISSN: 0143005X     EISSN: None     Source Type: Journal    
DOI: 10.1136/jech.51.4.354     Document Type: Article

References (53)

1. Anonymous. Interferon beta-1B-hope or hype? Drug Ther Bull 1996;34:9-11.
2. The IFNB Multiple Sclerosis Study Group. Interferon beta-1b in the treatment of multiple sclerosis: final outcome of the randomised controlled trial. Neurology 1995;45: 1277-85.
3. Kristiansen IV, Eggen AE, Thelle DS. Cost effectiveness of incremental programmes for lowering serum cholesterol concentration: is individual intervention worth while? BMJ 1991;302:1119-22.
4. Song F, Freemantle N, Sheldon TA, et al. Selective serotonin reuptake inhibitors: meta-analysis of efficacy and acceptability. BMJ 1993;306:683-87.
5. Montgomery SA, Henry J, McDonald G, et al. Selective serotonin reuptake inhibitors: meta-analysis of discontinuation rates. Int Clin Psychopharmacol 1994;9:47-53.
6. Anderson IM, Tomenson BM. Treatment discontinuation with selective serotonin reuptake inhibitors compared with tricyclic antidepressants: a meta-analysis. BMJ 1995;310: 1433-38.
7. Montgomery SA, Kasper S. Comparison of compliance between serotonin reuptake inhibitors and tricyclic antidepressants: a meta-analysis. Int Clin Psychophamiacol 1995;9(suppl 4):33-40.
8. Anderson IM, Tomenson BM. The efficacy of selective serotonin re-uptake inhibitors in depression: a meta-analysis of studies against tricyclic antidepressants. J Psychopharmacol 1995;8:238-49.
9. Hotopf M, Hardy R, Lewis G. Discontinuation rates of SSRIs and Tricyclic antidepressants: a meta-analysis and investigation of heterogeneity. Br J Psychiatry 1997;170: 120-27.
10. Freemantle N, House A, Song F, Mason JM, Sheldon TA. Prescribing selective serotonin reuptake inhibitors as a strategy for prevention of suicide. BMJ 1994;309:249-53.
11. Effective Health Care. The treatment of depression in primary care. Effective Health Care Bulletin 1993;5:
12. Department of Health. Assessing the effects of health technologies. London: Department of Health, 1992;
13. Upward JW, Edwards JG, Goldie A, Waller DG. Comparative effects of fluoxetine and amitriptyline on cardiac function. Br J Clin Pharmacol 1988;26:399-402.
14. Staner L, Kerhofs M, Detroux D, Leyman S, Linkowski P, Mendlewicz J. Acute, subchronic and withdrawal sleep EEG changes during treatment with paroxerine and amitriptyline: a double-blind randomized trial with major depression. Sleep 1995;18:470-77.
15. Kasper S, Voll, Viera A, Kick H. Response to total sleep deprivation before and during treatment with fluvoxamine or maprotiline in patients with major depression-results of a double blind study. Pharmocopsychiatry 1990;23:135-42.
16. Fudge JL, Perry PJ, Garvey MJ, Kelly MW. A comparison of the effect of fluoxetine and trazodone on the cognitive functioning of depressed outpatients. J Affect Disord 1990;18:275-80.
17. Ravindram AV, Teehan Md, Bakish D, et al. The impact of sertraline, desipramine and placebo on psychomotor functioning in depression. Human Psychopharmacol 1995;10:273-81.
18. Schulz KF, Chalmers I, Hayes RJ, Altman DG. Empirical evidence of bias. JAMA 1995;273:408-12.
19. Sackett DL, Oxman AD. The Cochrane Collaboration hand-book. Oxford: Cochrane Collaboration, 1994;
20. Schwanz JA, Speed NM, Branberg JA, Brewer TL, Brown M, Greden JF. Depression in stroke rehabilitation. Biol Psychiatry 1993;33:694-99.
21. Hamilton M. A rating scale for depression. J Neural Neurosurg Psychiatry 1960;23:56-62.
22. Hamilton M. Development of a rating scale for primary depressive illness. Br J Soc Clin Psychol 1967;6:278-96.
23. Montgomery SA, Åsberg MA. A new depression scale designed to be sensitive to change. Br J Psychiatry 1979;134: 382-89.
24. Wing JK, Cooper JE, Sartorius N. The measurement and classification of psychiatric symptoms. Cambridge: Cambridge University Press, 1974;
25. Robin LN, Helzer JE, Croughan J, Ratcliff KS. National Institute of Mental Health diagnostic interview schedule; its history, characteristics and validity. Arch Gen Psychiatry 1981;38:381-89.
26. Lewis G, Pelosi AJ, Araya R, Dunn G. Measuring psychiatric disorder in the community: a standardised assessment for lay interviewers. Psychol Med 1992;22:465-86.
27. Cicchetti DV, Prussoff BA. Reliability of depression and associated clinical symptoms. Arch Gen Psychiatry 1983;40:987-90.
28. Rabkin JG, Klein DF. The clinical measurement of depressive disorders. In: Marsella AJ, Hirschfeld RMA, Katz MM, eds. The measurement of depression. New York: Guilford, 1987;30-83.
29. Lewis G. Assessing psychiatric disorder with a human interviewer or a computer. J Epidemiol Community Health 1994;48:207-10.
30. Greist JH, Klein MH, Erdman HP, Bires JK, Machtinger PE, Kresge DG. Comparison of computer- and intervieweradministered versions of the diagnostic interview schedule. Hospital and Community Psychiatry 1987;38: 1304-11.
31. Fitzpatrick R, Fletcher A, Gore S, Jones D, Spiegelhalter D, Cox D. Quality of life measures in health care: I: applications and issues in assessments. BMJ 1992;305: 1074-77.
32. Fletcher A, Gore S, Jones D, Fitzpatrick R, Spiegelhalter D, Cox D. Quality of life measures in health care. II: design, analysis and interpretation. BMJ 1992;305:1145-48.
33. Spiegelhalter D, Gore S, Fletchcr A, Jones D, Cox D. Quality of life measures in health care. Ill resource allocation. BMJ 1992;305:1205-09.
34. Pocock SJ. A perspective on the role of quality of life assessment in clinical trials. Controlled Clinical Trials 1991;12(suppl 4):257s-65s.
35. Wells KB, Stewart A, Hays RD, et al. The functioning and well-being of depressed patients: results from the medical outcomes study. JAMA 1989;262:914-19.
36. La Pia S, Giorgio D, Ciriello R, et al. Double blind controlled study to evaluate the effectiveness and tolerability of fluoxetine versus mianserin in the treatment of depressive disorders among the elderly and their effects on cognitive behavioural parameters. New Trends in Experimental and Clinical Psychiatry 1992;8:139-46.
37. Stewart AD, Hays RD, Ware JE. The MOS short-form general health survey. Med Care 1988;26:724-32.
38. Bergner M, Bobbitt RA, Cartner WB, Gilson BS. The sickness impact profile: development and final revision of a health status measure. Med Care 1981;19:787-805.
39. Drummond MF, Stoddard GL, Torrance GW. Methods for the economic evaluation of heath care. Oxford: Oxford University Press, 1987;
40. Jonsson B, Bebbington PE. What Price Depression? The cost of depression and the cost-effectiveness of pharmacological treatment. Br J Psychiatry 1994;164:665-73.
41. Beuzen JN, Ravily VF, Souetre EJ, Thomander L. Impact of fiuoxetine on work loss in depression. Int J Psychopharmacol 1993;8:319-21.
42. Boyer WF, Feighner JP. The financial implications of starting treatment with a selective serotonin reuptake inhibitor or tricyclic antidepressant in drug-naive depressed patients. In: Jonsson B, Rosenbaum J, eds. Health economics of depression. London: John Wiley & Son Ltd, 1993;65-75.
43. Le Pen C, Levy E, Ravily V, Beuzen JN, Meurgey F. The cost of treatment dropout in depression. A cost benefit analysis of fluoxetine vs tricyclics. J Affect Disord 1994;31: 1-18.
44. Hotopf MH, Lewis G, Normand C. Are SSRIs a cost effective alternative to tricyclics? Br J Psychiatry 1996;168: 404-9.
45. Paykel ES, Priest RG. Recognition and management of depression in general practice: consensus statement. BMJ 1992;305:1198-1202.
46. Paykel E. The background: extent and nature of the disorder. In: Herbst K, Paykel E, eds. Depression: an integrative approach. Oxford: Heinemann, 1989;3-17.
47. Blacker CVR, Clare AW. Depressive disorder in primary care. Br J Psychiatry 1987;150:737-51.
48. Johnson DAW. Treatment compliance in general practice. Acta Psychiatr Scand 1981;63 (suppl 209):447-53.
49. Kuhs H, Rudolf GAE. A double-blind study of the comparative antidepressant effect of paroxetine and amitriptyline. Acta Psychiatr Scand 1989;80 (suppl 350): 145-146.
50. Piccinelli M, Wilkinson G. Outcome of depression in psychiatric settings. Br J Psychiatry 1994;164:297-304.
51. Loonen AJ, Peer PG, Zwanikken GJ. Continuation and maintenance therapy with antidepressive agents. Aletaanalysis of research (see comment). Pharm World Sci 1991;13:167-75.
52. Montgomery SA, Duphour H, Brion S, et al. The prophylactic efficacy of fluoxetine in unipolar depression. Br J Psychiatry 1988;153 (suppl 3):69-76.
53. Hotopf MH, Lewis G, Normand C. The treatment of depression: evaluation and cost-effectiveness, London: London School of Hygiene and Tropical Medicine, 1996.